ANDREW J JOHNSRUD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology SUGAR LAND, TX NPI 1164865705
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX Daiichi Sankyo Inc. All categories
General Payments — all program years on this page
$5,819.21
- Category: General Payments
- Program years: PY2022–2024
- Record count: 228
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,000.53 across 73 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,769.26 | 70 |
| Education | $231.27 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $216.91 | 6 |
| Janssen Biotech, Inc. | $200.35 | 9 |
| PFIZER INC. | $196.82 | 8 |
| Astellas Pharma US Inc | $172.68 | 5 |
| Merck Sharp & Dohme Corporation | $143.18 | 6 |
| Tempus AI, Inc | $137.25 | 3 |
| ABBVIE INC. | $108.50 | 4 |
| EISAI INC. | $87.40 | 3 |
| Apellis Pharmaceuticals, Inc. | $87.20 | 2 |
| Celgene Corporation | $61.70 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $61.55 | 2 |
| Acerta Pharma LLC | $60.79 | 2 |
| Incyte Corporation | $58.16 | 3 |
| Gilead Sciences, Inc. | $53.29 | 2 |
| ADC Therapeutics America, Inc. | $47.95 | 2 |
| GlaxoSmithKline, LLC. | $38.80 | 2 |
| PharmaEssentia USA Corporation | $31.62 | 1 |
| TAIHO ONCOLOGY, INC. | $31.14 | 2 |
| PUMA BIOTECHNOLOGY, INC. | $30.50 | 2 |
| ARRAY BIOPHARMA INC | $29.77 | 1 |
| SOBI, INC | $28.30 | 1 |
| TOLMAR, INC. | $24.88 | 1 |
| Alexion Pharmaceuticals, Inc. | $24.68 | 1 |
| E.R. Squibb & Sons, L.L.C. | $23.36 | 1 |
| BeiGene USA, Inc. | $23.22 | 1 |
| AVEO Pharmaceuticals, Inc. | $20.53 | 1 |
By program year
Records — PY2024 (73)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.